BUZZ-BioAge Labs edges down after stock sale hiked to $115 mln

Reuters01-22 21:34
BUZZ-<a href="https://laohu8.com/S/BIOA">BioAge Labs</a> edges down after stock sale hiked to $115 mln

** BioAge Labs BIOA.O shares down 0.3% before the bell at $20.06 after co raises more equity than planned

** Emeryville, California-based biopharma late Weds sold ~5.9 mln shares, about 16% of total outstanding, at $19.50 for $115 mln gross proceeds

** Offering price represents 3.1% discount to stock's last close

** BIOA shares on Weds finished down 5.6% after co late Tues unveiled $75 mln offering

** Co intends to use net offering proceeds to fund research, clinical development and manufacturing of its product candidates, including lead candidate BGE-102, a small-molecule NLRP3 inhibitor being developed for cardiovascular risk and retinal diseases, among other purposes

** Goldman Sachs, Piper Sandler and Citigroup joint bookrunners

** Through Weds, BIOA shares up 52% to begin 2026 and have more than tripled over the past three months

** 1 analyst rates the stock "strong buy", 3 rate "hold"; PTs are $9, $12 and $15, per LSEG data

(Lance Tupper is a Reuters market analyst. The views expressed are his own)

((lance.tupper@tr.com 1-646-279-6380))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment